Informations générales (source: ClinicalTrials.gov)
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
Interventional
N/A
Institut Curie (Voir sur ClinicalTrials)
janvier 2017
janvier 2032
02 mars 2026
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples
at different time points in ovarian, triple negative breast, Head and Neck Cancer,
advanced stage treatment-naïve cervical or vulva cancer and sarcoma (breast angiosarcoma
and uterine sarcoma) cancers. This study will allowed to identify new molecular and/or
immunological biomarkers associated with clinical and biological features of the tumors.
All patients will receive standard treatment according to the stage of the diseases and
usual procédures.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 10/04/2025 13:12:19 | Contacter | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 10/04/2025 13:12:03 | Contacter | |||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CLCC RENE HUGUENIN INSTITUT CURIE | Nicolas POUGET, MD | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Leon Berard - 69373 - Lyon 2996944 - France | Nicolas CHOPIN, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Oscar Lambret - 59000 - Lille 2998324 - France | Camille PASQUESOONE, MD | Contact (sur clinicalTrials) | |||
| Institut Bergonie - 33076 - Bordeaux 3031582 - France | Adeline PETIT, MD | Contact (sur clinicalTrials) | |||
| Institut Curie - 75005 - Paris 2988507 - France | Edith BORCOMAN, MD | Contact (sur clinicalTrials) | |||
| Institut de Cancérologie de Lorraine - Nancy - Vandœuvre-lès-Nancy 2970797 - France | Romina MASTRONICOLA, M | Contact (sur clinicalTrials) | |||
Critères
Tous
1. Tumor types :
1. Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or
neoadjuvant chemotherapy
2. Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible
for surgery or neoadjuvant chemotherapy
3. Newly diagnosed treatment-naïve head and neck cancer patients eligible for
surgery
4. Newly diagnosed treatment-naïve vulva cancer (all types) or cervical cancer
patients with (1) stage Ia - IIa1 with nodal metastasis, postoperative positive
margin or parametrial-vaginal involvement, and (2) stage ≥IIa2).
5. Newly diagnosed treatment-naïve sarcoma cancer patients (1) breast angiosarcoma
or (2) uterine sarcoma eligible for surgery or systemic treatment
2. Male or female patients ≥ 18 years of age
3. Signed informed consent
Exclusion Criteria:
1. Male or female patients ≤18 years old
2. Patients with any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule
3. Individually deprived of liberty or placed under the authority of a tutor
4. Patients not affiliated to the Social Security System